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Docetaxel enhances the cytotoxic effects of
imatinib on Philadelphia positive human
chronic myeloid leukemia cells
Gozde Gucluler and Yusuf Baran
Izmir Institute of Technology, Department of Molecular Biology and Genetics, 35430, Urla, Izmir,
Turkey
Chronic myelogenous leukemia (CML) results from a translocation between chromosomes 9 and
22 which generates BCR/ABL fusion protein and characterized by uncontrolled proliferation of
immature white blood cells. Imatinib, a molecularly targeting anticancer agent, is used widely for
the treatment of CML and showed significant activity in chronic and accelerated phases but much
less in blast crisis phase. The resistance to imatinib especially in blast crisis phase is recognized
as a major problem in the treatment of CML patients. Docetaxel is shown to arrest cells in G2/M
phase of the cell cycle which makes cells more sensitive to chemo- and radiotherapy. In this
study, we aimed to increase chemosensitivity of human K562 CML cells to imatinib in combination
with docetaxel. Taken together, our results showed that the combination of imatinib and docetaxel
decreased cellular proliferation and increased apoptosis in human K562 chronic myeloid
leukemia cells as compared to any agent alone. Imatinib and docetaxel induced apoptosis
through caspase-3 enzyme activity and mitochondrial membrane potential.
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Introduction
Imatinib (imatinib mesylate, STI571, Gleevec) is a
widely used anticancer agent for the treatment of
chronic myeloid leukemia (CML).1–3 Chronic mye-
loid leukemia is a hematopoietic stem cell disorder
which is the result of the reciprocal translocation
between chromosomes 9 and 22. This translocation
forms a fusion protein gathering two genes, the BCR
gene from chromosome 22 and the ABL gene from
chromosome 9. BCR/ABL fusion protein is encoded
by this hybrid gene with a constitutive tyrosine kinase
activity inducing cellular proliferation, preventing
apoptosis and decreasing cellular adhesion.2,4–6
Development of imatinib is an important avenue
for the treatment of CML. Imatinib is able to
recognize and bind to 21 amino acids of the BCR/
ABL ATP-binding site. Binding of imatinib to that
site will inhibit the autophosphorylation of BCR/
ABL and thus its substrates.2,6,7 In the beginning,
imatinib presented very high hematological and
cytogenetic responses in chronic and accelerated
phases of CML patients. But, in blast crisis phase,
the emergence of hematologic and cytogenetic
resistance to imatinib is recognized as a major
problem in the treatment of patients with CML.2,3,6,8
Docetaxel is an anticancer agent which induces
apoptosis by suppressing the microtubule dynamics
of the mitotic apparatus. Docetaxel binds to taxel
side of the b-tubulin stabilizing the microtubules and
promotes the polymerization of microtubules. Thus,
depolymerization of microtubules into free tubulin
monomers is prevented causing inhibition of the
metaphase anaphase transition, blocking mitosis and
inducing apoptosis. Besides inducing cell death,
docetaxel arrests cells in G2/M phase altering the
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centromere organization as a microtubule-stabilizing
agent.9,10 By this G2/M arrest ability, docetaxel has
been shown to increase the sensitivity of cancer cells
to chemotherapy and radiotherapy besides inhibiting
cell proliferation.11
In this study, we tried to increase sensitivity of
K562 cells to imatinib by combination with docetaxel
and showed the responsible signaling pathways that
induce apoptosis.
Methods
Cell lines and culture conditions
K562 human CML cells were obtained from the
German Collection of Microorganisms and Cell
Cultures. These cells were cultured in RPMI 1640
growth medium containing 10% fetal bovine serum
and 1% penicillin-streptomycin (Invitrogen) at 37uC
in 5% CO2.
Measurement of cell growth by XTT
The IC50 values (the drug dose in which the 50% of
cells can survive) of imatinib and docetaxel were
determined by XTT as described previously.9 Briefly,
96-well plates were seeded with 26104 cells/well
containing 100 ml of the growth medium in the
absence or presence of increasing concentrations of
imatinib and docetaxel. They were incubated at 37uC
in 5% CO2 for 72 h. Then, they were treated with
40 ml XTT for 4 h. After that, plates were read under
490 nm wavelengths by Elisa reader (Thermo
Electron Corporation Multiskan Spectrum,
Finland). Finally, IC50 values were calculated
according to cell survival plots.
Measurement of caspase-3 enzyme activity
Caspase-3 enzyme activity of the cells was assessed
using the caspase-3 colorimetric assay kit (R&D
Systems, USA) as described previously.4 Firstly, the
cells that had been induced to apoptosis were
collected by centrifugation at 1000 rpm for 10 min.
Then, the collected cells were lysed by adding 100 ml
of cold lysis buffer (16). After incubation of the cells
on ice for 10 min, they were centrifuged at 14000 rpm
for 1 min. Supernatants were removed to new
Eppendorf tubes and the reaction mixture was
prepared in 96-well plates adding 20 ml assay buffer
(56), 25 ml of sample, 50 ml of sterilized water and
5 ml of caspase-3 colorimetric substrate. After 2 h
incubation at 37uC, the plate was read under 405 nm
wavelength light (Thermo Electron Corporation
Multiskan Spectrum, Finland)
Detection of the loss of mitochondrial membrane potential
(MMP)
APO LOGIX JC-1 Assay Kit (Cell Technology,
USA) was used to measure the mitochondrial
membrane potential in K562 cells as described
previously.5 JC-1, a unique cationic dye, was used
to determine the loss of the MMP. In the beginning,
the cells that had been induced to apoptosis were
collected by centrifugation at 1000 rpm for 10 min.
Supernatants were removed and 500 ml of JC-1 dye
was added onto the pellets. After incubation at 37uC
in 5% CO2 for 15 min, they were centrifuged at
1000 rpm for 5 min. Then, 2 ml of assay buffer was
added onto the pellets which were centrifuged for
5 min at 1000 rpm. All pellets were resuspended with
500 ml assay buffer and 150 ml from each of them was
added into the 96-well plate. The aggregate red form
has absorption/emission maxima of 585/590 nm and
the green monomeric form has absorption/emission
maxima of 510/527 nm. The plate was read in these
wavelengths by fluorescence Elisa reader (Thermo
Varioskan Spectrum, Finland).
Phosphatidylserine exposure
Apoptotic cell death was evaluated by using annexin
V/propidium iodide double staining method based on
apoptosis-related cell membrane modifications.
Firstly, cells that had been induced to apoptosis were
washed with cold PBS and then resuspended in 16
binding buffer. 100 ml from each solution was
transferred to Eppendorf tubes. Five microliters
Annexin V-FITC and 5 ml PI was added on the cells.
After gentle vortexing, they were incubated for
15 min at room temperature in the dark. Four
hundred microliters 16 binding buffer was then
added into each tube and they were analyzed by flow
cytometry (BD Facscanto flowcytometry, Belgium)
within 1 h.
Results
Docetaxel or imatinib showed a dose-dependent
cytotoxicity on human K562 chronic myeloid leukemia cells
We have shown antiproliferative effects of docetaxel
or imatinib on K562 cells exposed to increased
concentrations of the drugs by XTT cell proliferation
assay. The results showed that there were dose
dependent decreases in cell proliferation as compared
to untreated controls. There were 12, 16, and 26%
decreases in cell proliferation in 1, 10, and 100 nM
imatinib applied K562 cells, respectively, as com-
pared to untreated controls (Fig. 1). On the other
hand, in K562 cells exposed to 1, 10, and 100 nM
docetoxel, there were 10, 67 and 75% decreases in cell
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proliferation, respectively, as compared to untreated
controls. IC50 values of imatinib (Fig. 1) and
docetaxel (Fig. 2) in K562 cells were calculated from
cell proliferation plots and were found to be 280 and
7.3 nM, respectively.
Synergistic/additive effects of docetaxel and imatinib on
human K562 chronic myeloid leukemia cells
To examine the possible synergistic/additive cytotoxic
effects of docetaxel and imatinib, K562 cells were
exposed to combination of IC50 levels of docetaxel
(7.3 nM) and increasing concentrations of imatinib
from 0.1 to 1000 nM and proliferation rates were
determined by XTT cell proliferation assay. There
were 6, 12, 16, 26, and 80% decreases in cell
proliferation in 0.1, 1, 10, 100, and 500 nM imatinib
treated K562 cells, respectively, while the combina-
tion of these doses with 7.3 nM docetaxel (IC50
value) resulted in 53, 57, 62, 81, and 93% decreases
cell proliferation, respectively, as compared to
untreated controls (Fig. 3). These results strongly
suggest that the combination of imatinib and
docetaxel has shown significant cytotoxic effect,
comparing any agent alone, in human K562 chronic
myeloid leukemia cells.
Significant increase in caspase-3 enzyme activity
determined in response to combination of imatinib and
docetaxel as compared to any agent alone
Caspase-3 enzyme activity was measured to show the
synergistic effects of imatinib and docetaxel on K562
cells. The K562 cells exposed to 7.3 nM docetaxel, 10
and 280 nM imatinib alone presented 1.7-, 1.3- and
1.6-fold increases in caspase-3 enzyme activity,
respectively, as compared to untreated controls. On
the other hand combination of 7.3 nM docetaxel with
10 or 280 nM imatinib resulted in 2 and 2.4-fold
increase in caspase-3 activity in K562 cells, respec-
tively, compared to untreated controls (Fig. 4).
Synergistic effects of combination of imatinib and
docetaxel on mitochondrial membrane potential in K562
cells
To confirm the synergistic effect of the combination
of imatinib and docetaxel, mitochondrial membrane
potential (MMP) was measured by JC-1 MMP Assay
Kit. Cells were treated with 7.3 nM docetaxel,
10 nM, 280 nM imatinib alone and the combination
of 7 nM docetaxel and 10 or 280 nM imatinib. There
were 1.3-, 1.3- and 1.5-fold increases in cytoplasmic/
monomeric JC-1 in 7.3 nm docetaxel, 10 and 280 nm
imatinib alone treated K562 cells, respectively,
compared to control cells (Fig. 5). Combination of
7.3 nM docetaxel with the same doses of imatinib
increased the cytoplasmic/monomeric JC-1, 1.6- and
17-fold, respectively, as compared to untreated
controls (Fig. 5).
Combination of imatinib and docetaxel induced human
K562 CML cells to apoptosis
Apoptosis and cell viability in K562 cells were
measured by AnnexinV-FITC staining by flow
cytometry. As shown in Fig. 6, there were 15.5, 16.4
and 25.1% increases in apoptosis in response to
7.3 nM docetaxel, 10 and 280 nM imatinib in K562
cells, respectively. Exposure of K562 cells to the
combination of 7.3 nM docetaxel and 10 or 280 nM
imatinib increased the apoptosis percentage 26.1 and
37.2% respectively.
Discussion
Treatment of cancer with more than one agent is
called combination therapy. In combination therapy,
to increase the effect of the one agent, another agent
which has different effective mechanism can be used.
Recent studies have shown that because treating
different targets gives more effective results, combi-
nation therapy is a good alternative way for the
treatment of cancer.12–14
Chronic myeloid leukemia is the result of the
reciprocal translocation between chromosomes 9 and
22. This translocation between these two chromo-
somes causes the formation of BCR/ABL fusion
protein.5,9 BCR/ABL fusion protein contributes
many signaling pathways in cell-cycle showing high
tyrosine kinase activity resulting in CML. Imatinib
which is the first generation of the tyrosine kinase
inhibitors, is used in the treatment of CML targeting
the tyrosine kinase site of the BCR/ABL fusion
protein. It binds to the ATP-binding side and inhibits
the tyrosine kinase activity of BCR/ABL.5,9,15 Recent
studies have shown that CML patients have well
responses to imatinib at chronic and accelerated
phases. But, the emergence of resistance to imatinib
at blast crisis phase complicates the CML treatment
with imatinib. Combination therapy is an alternative
way to treat the diseases with more than one agent.
The object of this application is to enhance the effect
of the one agent with some other agents. In this
study, we aimed to increase the efficiency of imatinib
on Philadelphia chromosome positive K562 cells with
a combination of docetaxel.
Imatinib/docetaxel combination has been used
recently for the treatment of different types of cancers
by different groups. In one study, it was shown
that the imatinib/docetaxel combination showed
significant cytotoxic effect for the treatment of
androgen-independent prostate cancer (AIPC).10
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Imatinib/docetaxel combination was also applied for
the patients with advanced, platinum-resistant ovar-
ian cancer and primary peritoneal carcinomatosis
together and the results indicated that there was little
induction of responses for heavily pretreated
patients.16
There are some other studies used combinations of
imatinib with some other agents to increase the
susceptibility of BCR/ABL positive CML cells.
Kancha and his coworkers emphasized the effective-
ness of combination of imatinib and a nuclear
transport blocker, leptomycin B, to imatinib-resistant
Ba/F3 cells.17 In another study, imatinib applied to
neuroblastoma cells combining with retinoic acid and
c-irritation. The results showed that there were
synergistic cytotoxic effects of imatinib and retinoic
acid application as compared to any agent alone.18
Docetaxel has also been used as a chemosensitising
agent for the treatment of different types of cancer
with different anticancer agents. Docetaxel with a
combination of zoledronic acid showed significant
cytotoxicity as compared to only zoledronic acid
applied hormone-sensitive prostate carcinoma cells.
The combination of these agents presented high
Figure 1 Effects of imatinib on the growth of K562 cells.
The IC50 concentration of imatinib was calcu-
lated from cell proliferation plots. The XTT
assays were performed using triplicate samples
in at least two independent experiments. The
error bars represent the standard deviations,
and when not seen, they are smaller than the
thickness of the lines on the graphs. Statistical
significance was determined using two-way ana-
lysis of variance, and p,0.05 was considered
significant
Figure 2 Effects of docetaxel on the growth of K562 cells.
The IC50 concentration of zoledronic acid was
determined by XTT assay for each cell line as
described. The XTT assays were performed
using triplicate samples in at least two indepen-
dent experiments. The error bars represent the
standard deviations, and when not seen, they
are smaller than the thickness of the lines on
the graphs. Statistical significance was deter-
mined using two-way analysis of variance, and
p,0.05 was considered significant
Figure 3 Effects of docetaxel and imatinib combination
on the growth of K562 cells. Cytotoxicity was
determined by the XTT cell proliferation test in a
72 h culture. The XTT assays were performed
using triplicate samples in at least two indepen-
dent experiments. The error bars represent the
standard deviations, and when not seen, they
are smaller than the thickness of the lines on
the graphs. Statistical significance was deter-
mined using two-way analysis of variance, and
p,0.05 was considered significant
Figure 4 Percent changes in caspase-3 enzyme activity in
docetaxel and imatinib combination or any agent
alone exposed K562 cells. The results are the
means of two independent experiments. The
error bars represent the standard deviations,
and when not seen, they are smaller than the
thickness of the lines on the graphs. p,0.05
was considered significant
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synergistic effect on the induction of the apoptosis on
LnCap cells.19 In one another study, docetaxel was
applied to hormone-refractory prostate cancer
(HRPC) with a combination of bevacizumab and
showed synergistic apoptotic effect on HRPC cells.
Results showed that the combination of docetaxel
and bevacizumab is tolerable and active for HRPC
patients.20 It was also shown by different studies that
the combination of docetaxel and gemcitabine had
synergistic cytotoxic effect for the treatment of the
pediatric sarcomas and for elderly patients with lung
adenocarcinomas. The results of this study indicated
that the combination of docetaxel with gemcitabine
had effective and tolerable antitumor activity in
both sarcomas and elderly patients with lung
adenocarcinomas.21,22
In parallel with the literature, our results strongly
indicated that docetaxel increased the chemosensitiv-
ity of BCR/ABL positive human K562 chronic
myeloid leukemia cells to imatinib. Imatinib/
docetaxel combination induces apoptosis through
decrease in mitochondrial membrane potential and
increase in caspase-3 enzyme activity.
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